Shingles Shot Shows Short-Term Safety in People With HIV
A recent study found that the herpes zoster vaccine has a favorable short-term safety profile for people living with HIV. Participants showed excellent adherence to the two-dose schedule, with a high completion rate. The study's findings may help reassure patients about the vaccine's safety.
- ▪The study involved 237 participants aged 18 years or older across six centers in Spain.
- ▪82.7% of participants reported adverse events after vaccination, with local pain being the most common.
- ▪No cases of Guillain-Barré syndrome were detected, and adherence to the vaccination schedule was 99.60%.
Medscape files mainly under health. We currently carry 231 of its stories.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | Medscape |
| Canonical URL | https://www.medscape.com/viewarticle/shingles-shot-shows-short-term-safety-people-hiv-2026a1000h4v?src=rss |
| Publication time | Tue, 26 May 2026 06:33:28 EDT |
| Retrieval time | 2026-05-26T10:37:48.036Z |
| Last seen | 2026-05-26T10:37:48.036Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | KLsCtMFdBQ8Y |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
TOPLINE:The adjuvanted recombinant subunit herpes zoster vaccine showed a favorable short-term safety and tolerability profile in people living with HIV (PLWH), with participants showing excellent adherence to the two-dose schedule.METHODOLOGY:This prospective real-world study monitored vaccination-related adverse events (AEs) after each dose of the adjuvanted recombinant subunit herpes zoster vaccine in PLWH aged 18 years or older.A total of 237 PLWH (84.81% men) received at least one dose of the vaccine across six centers in Spain between June 2022 and February 2024.Participants recorded AEs for 10 days after each dose, along with their duration and any treatments used, and healthcare professionals later reviewed the events through a follow-up phone call.The primary outcome was the…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Medscape.
Discussion
0 commentsMore from Medscape
